Eloxatin Has 38% Share Of First-Line Colorectal Cancer Market, Sanofi Says
Executive Summary
Sanofi-Synthelabo's Eloxatin has taken a greater than one-third share of the first-line advanced colorectal cancer market from Camptosar ahead of FDA approval, Exec VP-Operations Hanspeter Spek said